Lead Product(s): Protein therapeutics
Therapeutic Area: Neurology
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Takeda Pharmaceutical
Deal Size: $882.0 million Upfront Cash: $44.0 million
Deal Type: Partnership March 26, 2020
Deal allows Evox to continue advancing its exosome-based targeting and delivery technology, while also leveraging Takeda’s development and clinical expertise to advance these partnered programmes.